CCN2 and pancreatic neoplasm: However, the study was discontinued as it did not support a clinical benefit.[20] In a different example, pamrevlumab, a mAB against connective tissue growth factor (CTGF), is under phase III study as a neoadjuvant for chemotherapy in advanced unresectable pancreatic cancer (clinicaltrials.gov identifier: NCT03941093) and in metastatic pancreatic cancer (NCT04229004).